Financial Performance - The company's operating revenue for Q3 2023 reached ¥111,976,469.19, representing a year-on-year increase of 35.80%[5] - Net profit attributable to shareholders for Q3 2023 was ¥31,123,723.10, up 30.16% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period was ¥90,764,915.31, reflecting an increase of 89.49% year-on-year[5] - Total revenue for the first three quarters of 2023 reached ¥331,773,648.23, a significant increase of 53.3% compared to ¥216,579,425.15 in the same period of 2022[24] - Operating profit for the first three quarters of 2023 was ¥111,534,676.18, up 68.1% from ¥66,339,553.58 in the previous year[25] - Net profit attributable to shareholders for the first three quarters of 2023 was ¥101,681,102.97, representing a 63.5% increase from ¥62,168,808.28 in 2022[25] - Basic earnings per share for the first three quarters of 2023 was ¥1.4901, compared to ¥0.9102 in the same period last year[26] - The total comprehensive income for the first three quarters of 2023 was ¥101,681,102.97, compared to ¥62,168,808.28 in the same period of 2022[26] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,740,907,249.50, a 3.37% increase from the end of the previous year[6] - As of September 30, 2023, the company's total assets amounted to RMB 1,740,907,249.50, an increase from RMB 1,684,216,383.26 at the end of 2022, reflecting a growth of approximately 3.4%[19] - The company's total liabilities decreased to RMB 1,225,290,937.16 from RMB 1,319,209,552.01, a reduction of about 7.1%[17] - Total liabilities as of the end of Q3 2023 amounted to ¥152,000,556.82, a decrease from ¥155,669,156.83 at the end of 2022[20] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥71,542,748.02, showing a significant increase of 376.41%[6] - Operating cash inflow for Q3 2023 was $402,479,751.93, up from $246,363,549.38 in Q3 2022, representing a year-over-year increase of approximately 63.5%[29] - Total cash inflow from operating activities was $71,542,748.02, a significant increase from $15,017,188.90 in Q3 2022, marking a growth of approximately 376.5%[29] - Cash received from sales of goods and services in the first three quarters of 2023 was ¥361,582,394.83, an increase of 63.3% from ¥221,293,394.88 in 2022[28] - Cash and cash equivalents at the end of Q3 2023 totaled $1,128,655,443.89, down from $1,259,859,726.40 at the end of Q3 2022, reflecting a decrease of about 10.4%[30] Research and Development - Research and development expenses for Q3 2023 totaled ¥19,724,628.55, which is 31.42% higher than the same period last year[6] - Research and development expenses for the first three quarters of 2023 were ¥41,705,282.25, up from ¥36,613,414.05 in the same period of 2022[24] Investments - The company has invested RMB 198,351,426.25 in construction projects, a substantial increase from RMB 70,441,742.07, reflecting a growth of approximately 181.5%[19] - Net cash outflow from investing activities was -$137,151,302.73, compared to -$21,207,329.51 in the same period last year, indicating a significant increase in cash used for investments[29] - Cash received from investment activities was $1,808,046,369.72, down from $2,914,417,314.10 in Q3 2022, indicating a decrease of approximately 38%[29] - Cash paid for investments was $1,822,000,000.00, which is the same as the previous year's figure of $2,895,000,000.00, showing no change year-over-year[29] Equity and Shareholder Information - The basic earnings per share for Q3 2023 was ¥0.4563, an increase of 30.33% year-on-year[6] - The weighted average return on equity for the year-to-date period was 6.51%, an increase of 2.46 percentage points compared to the previous year[6] - Total equity attributable to shareholders increased to ¥1,588,906,692.68 from ¥1,528,547,226.43 in the previous year[20] Other Information - The company implemented an equity incentive plan resulting in share-based payment expenses (after tax) of ¥9,135,400.00[6] - The company has not reported any significant new product launches or market expansions during this quarter[17] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[6]
伟思医疗(688580) - 2023 Q3 - 季度财报